TY - JOUR
T1 - Diabetes, metabolic disease, and telomere length
AU - Cheng, Feifei
AU - Carroll, Luke
AU - Joglekar, Mugdha V.
AU - Januszewski, Andrzej S.
AU - Wong, Kwun Kiu
AU - Hardikar, Anandwardhan A.
AU - Jenkins, Alicia J.
AU - Ma, Ronald C. W.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/2
Y1 - 2021/2
N2 - Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular disease, diabetes, and cancer. Emerging studies have highlighted the role of genetic and environmental factors, and explored the effect of modulating telomere length. We provide an overview of studies to date on diabetes and telomere length, and compare different methods and assays for evaluating telomere length and telomerase activity. We highlight the limitations of current studies and areas that warrant further research to unravel the link between diabetes and telomere length. The value of adding telomere length to clinical risk factors to improve risk prediction of diabetes and related complications also merits further investigation.
AB - Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular disease, diabetes, and cancer. Emerging studies have highlighted the role of genetic and environmental factors, and explored the effect of modulating telomere length. We provide an overview of studies to date on diabetes and telomere length, and compare different methods and assays for evaluating telomere length and telomerase activity. We highlight the limitations of current studies and areas that warrant further research to unravel the link between diabetes and telomere length. The value of adding telomere length to clinical risk factors to improve risk prediction of diabetes and related complications also merits further investigation.
UR - https://hdl.handle.net/1959.7/uws:60839
U2 - 10.1016/S2213-8587(20)30365-X
DO - 10.1016/S2213-8587(20)30365-X
M3 - Article
SN - 2213-8587
VL - 9
SP - 117
EP - 126
JO - Lancet Diabetes and Endocrinology
JF - Lancet Diabetes and Endocrinology
IS - 2
ER -